Developer competition : CagriSema (Novo Nordisk) versus retatrutide (Eli Lilly) represents the central competitive axis in next-generation obesity therapeutics
Par voie orale (comprims, gouttes, ampoules buvables) C'est la forme la mieux tolre
Peer-reviewed and received in revised form 11 January 2022
doi: 10.12932/AP-011117-0188
Reactions were performed with 2 M nicotinamide and 30 M phosphoribosyl pyrophosphate (PRPP) in the presence of 1mM ATP and recombinant human NAMPT enzyme
Testing must therefore characterize both the formulation (assay, purity, pH, osmolality, viscosity, microbial safety) and the device performance (spray pattern, plume geometry, droplet size distribution, dose uniformity, priming behavior) as an integrated system